Bridgebio Oncology Therapeutics, Inc. (BBOT)
8.51
+0.14
(+1.67%)
USD |
NASDAQ |
May 27, 16:00
8.51
0.00 (0.00%)
After-Hours: 17:33
Bridgebio Oncology Therapeutics Cash from Investing (Quarterly) : -285.41M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Praxis Precision Medicines, Inc. | -344.28M |
| Erasca, Inc. | -243.83M |
| Bicara Therapeutics, Inc. | 100.94M |
| Amgen, Inc. | -716.00M |
| BioMarin Pharmaceutical, Inc. | 725.53M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -35.92M |
| Cash from Financing (Quarterly) | 0.295M |
| Free Cash Flow | -149.71M |
| Free Cash Flow Per Share (Quarterly) | -449.26 |
| Free Cash Flow to Equity (Quarterly) | -35.82M |
| Free Cash Flow to Firm (Quarterly) | -35.94M |
| Free Cash Flow Yield | -47.85% |